Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma
Genes · 2025
DOI: 10.3390/genes16020138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Adrian Albulescu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Virology Department, Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania. Hauptthemen laut MEDLINE: Glioblastoma, Epigenesis, Genetic, Brain Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romanian Ministry of Research, Innovation and Digitalization, Romanian Academy.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Glioblastoma is the most common malignant primary brain tumor, characterized by necrosis, uncontrolled proliferation, infiltration, angiogenesis, apoptosis resistance, and genomic instability. Epigenetic modifiers hold promise as adjuvant therapies for gliomas, with synergistic combinations being explored to enhance efficacy and reduce toxicity. This study aimed to evaluate the effects of single or combined treatments with various anticancer drugs (Carboplatin, Paclitaxel, Avastin), natural compounds (Quercetin), and epigenetic modulators (suberoylanilide hydroxamic acid and 5-Azacytidine) on the expression of some long noncoding RNAs and methylation drivers or some functional features in the U87-MG cell line.
Methods
Treated and untreated U87-MG cells were used for the evaluation of drug-induced cytotoxicity, apoptotic events, and distribution in cell cycle phases, detection of cytokine release, and assessment of gene expression and global methylation.
Results
Cytotoxicity assays led to the selection of drug concentrations to be used in further experiments. Expression analysis revealed distinct downregulation of nearly all investigated genes and long noncoding RNAs following treatments. All treatments resulted in a higher percentage of global methylation compared to untreated controls. All treatments effectively increased levels of apoptosis, while the epigenetic modulators exhibited a lower proliferation profile, with combined treatments showing elevated values of cell lysis.
Conclusions
The results indicate a link between Carboplatin and Avastin treatments and DNA methylation mechanisms involving EZH2, DNMT3A, and DNMT3B, with Avastin’s direct impact on these enzymes warranting further study. This research underscores the promise of platinum-based therapies combined with epigenetic drugs to reactivate silenced tumor suppressor genes and optimize methylation profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Virology Department, Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
- Pharmacology Department, National Institute for Chemical Pharmaceutical Research and Development, 031299 Bucharest, Romania.
- Center of Immunology, Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
ORCID-Profile: Anca Botezatu, Marinela Bostan, Mirela Mihăilă
Förderung
- Romanian Ministry of Research, Innovation and Digitalization
- Romanian Academy
Zitieren
APA
Albulescu, A., Botezatu, A., Fudulu, A., Hotnog, C. M., Bostan, M., Mihăilă, M., Iancu, I. V., Plesa, A., & Brasoveanu, L. (2025). Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma. Genes. https://doi.org/10.3390/genes16020138
Vancouver
Albulescu A, Botezatu A, Fudulu A, Hotnog CM, Bostan M, Mihăilă M, et al. Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma. Genes. 2025. doi:10.3390/genes16020138
BibTeX
@article{Albulescu2025,
author = {Albulescu, Adrian and Botezatu, Anca and Fudulu, Alina and Hotnog, Camelia Mia and Bostan, Marinela and Mihăilă, Mirela and Iancu, Iulia Virginia and Plesa, Adriana and Brasoveanu, Lorelei},
title = {Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16020138}
}
EUVIMED